



ON-LINE FIG 1. SNR, relative signal enhancement, and mean CNR on 1.5T versus 3T.



ON-LINE FIG 2. Meningioma. Baseline (A), enhanced timeframe (B) of DCE perfusion, and contrast-enhanced fat-saturated T1 spin-echo (C) show an intradural extramedullary mass.



ON-LINE FIG 3. Schwannoma. Baseline (A), enhanced timeframe (B) of DCE perfusion, and contrast-enhanced fat-saturated T1 spin-echo (C) show an intradural extramedullary mass.



ON-LINE FIG 4. Representative enhancement curves of all the pathologies studied in this work: schwannoma (1.5T), meningioma (1.5T), metastasis (3T), glioblastoma (3T), low-grade astrocytoma (3T), myelitis (3T), ependymoma (1.5T), myxopapillary ependymoma (3T), and hemangioblastoma (3T), respectively.

On-line Table 1: Demographic and clinical features of the patients

No.	Sex	Age (yr)	Diagnosis	Confirmation
1	M	72	Spinal cord metastasis	Pathologic
2	M	39	Schwannoma	Pathologic
3	M	50	Hemangioblastoma	Von Hippel-Lindau
4	M	45	Spinal cord glioblastoma	Pathologic
5	M	44	Schwannoma	Pathologic
6	M	36	Grade II WHO fibrillary astrocytoma	Pathologic
7	M	55	Transverse myelitis	Clinico-radiologic follow-up (10 mo)
8	M	65	Meningioma	Pathologic
9	F	70	Meningioma	Pathologic
10	F	55	Grade II WHO ependymoma	Pathologic
11	M	24	Hemangioblastoma	Von Hippel-Lindau
12	F	65	Meningioma	Pathologic
13	M	56	Transverse myelitis	Clinico-radiologic follow-up (18 mo)
14	F	36	Hemangioblastoma	Von Hippel-Lindau
15	M	55	Grade I WHO myxopapillary ependymoma	Pathologic

Note:—WHO indicates World Health Organization.

On-line Table 2: Parameters of model-independent analysis and pharmacokinetic analysis of patients with intramedullary tumors and myelitis^a

	Metastasis	Hemangioblastoma	Glioblastoma	Low-Grade Tumors	Myelitis
AUC	30,974; 9026; 649	163,523; 42,767; 3624 ³ 60,393; 8624; 3984 ¹¹ 159,878; 54,608; 3924 ¹⁴	36,427; 12,430; 893	49,551; 18,986; 1364 ⁶ 16,050; 5723; 445 ¹⁰ 61,770; 20,810; 1495 ¹⁵	49,164; 10,950; 1313 ⁷ 6745; 3025; 291 ¹³
K^{trans} (Tofts model)	0.365; 0.171; 0.012	2.849; 1.425; 0.255 ³ 1.268; 0.705; 0.523 ¹¹ 1.719; 1.177; 0.13 ¹⁴	0.150; 0.075; 0.005	0.078; 0.102; 0.014 ⁶ 0.190; 0.130; 0.011 ¹⁰ 0.59; 0.26; 0.025 ¹⁵	0.165; 0.044; 0.006 ⁷ 0.032; 0.016; 0.002 ¹³
K^{trans} (Tofts extended model)	0.353; 0.223; 0.016	0.041; 0.108; 0.028 ³ NA ¹¹ 0.118; 0.412; 0.048 ¹⁴	0.062; 0.039; 0.003	0.078; 0.045; 0.006 ⁶ 0.21; 0.199; 0.021 ¹⁰ 0.566; 0.228; 0.021 ¹⁵	0.12; 0.034; 0.005 ⁷ 0.032; 0.018; 0.003 ¹³
v_e (Tofts model)	0.391; 0.103; 0.007	0.807; 0.162; 0.029 ³ 0.332; 0.034; 0.025 ¹¹ 0.631; 0.208; 0.023 ¹⁴	0.151; 0.066; 0.005	0.412; 0.203; 0.028 ⁶ 0.281; 0.137; 0.011 ¹⁰ 0.773; 0.164; 0.016 ¹⁵	0.339; 0.099; 0.013 ⁷ 0.142; 0.124; 0.013 ¹³
v_e (Tofts extended model)	0.395; 0.113; 0.008	0.436; 0.267; 0.055 ³ NA ¹¹ 0.304; 0.237; 0.027 ¹⁴	0.142; 0.105; 0.008	0.539; 0.244; 0.032 ⁶ 0.300; 0.150; 0.012 ¹⁰ 0.782; 0.150; 0.014 ¹⁵	0.482; 0.156; 0.019 ⁷ 0.135; 0.108; 0.011 ¹³
v_p (Tofts extended model)	0.026; 0.017; 0.001	0.594; 0.224; 0.023 ³ NA ¹¹ 0.489; 0.128; 0.009 ¹⁴	0.038; 0.019; 0.001	0.139; 0.058; 0.004 ⁶ 0.026; 0.021; 0.002 ¹⁰ 0.079; 0.043; 0.003 ¹⁵	0.030; 0.014; 0.002 ⁷ 0.006; 0.006; 0.001 ¹³
χ^2 (Tofts model)	380; 200; 14	12,835; 3184; 270 ³ 1697; 194; 90 ¹¹ 10,943; 4599; 330 ¹⁴	447; 565; 41	7529; 3465; 193 ⁶ 184; 172; 13 ¹⁰ 352; 187; 8 ¹⁵	411; 153; 21 ⁷ 251; 93; 9 ¹³
χ^2 (Tofts extended model)	376; 204; 15	3347; 834; 71 ³ 450; 120; 56 ¹¹ 5361; 2104; 151 ¹⁴	348; 510; 37	1300; 752; 42 ⁶ 148; 77; 6 ¹⁰ 304; 158; 6 ¹⁵	354; 155; 21 ⁷ 245; 98; 9 ¹³

Note:—NA indicates not applicable.

^a The superscript shows the patient number. Data are mean, SD, and 95% confidence value.

On-line Table 3: Parameters of model-independent analysis and pharmacokinetic analysis of patients with schwannomas and meningiomas^a

	Meningioma	Schwannoma
AUC	34,461; 7572; 685 ⁸ 27,203; 5093; 366 ⁹ 43,105; 8248; 756 ¹²	33,445; 9257; 1356 ² 43,874; 7396; 651 ⁵
K^{trans} (Tofts model)	0.438; 0.213; 19 ⁸ 0.219; 0.067; 5 ⁹ 0.857; 0.206; 19 ¹²	0.332; 0.174; 0.025 ² 0.533; 0.165; 0.015 ⁵
K^{trans} (Tofts extended model)	0.238; 0.171; 16 ⁸ 0.174; 0.064; 5 ⁹ 0.333; 0.084; 8 ¹²	0.324; 0.139; 0.020 ² 0.375; 0.118; 0.010 ⁵
v_e (Tofts model)	0.154; 0.036; 0.003 ⁸ 0.4; 0.073; 0.005 ⁹ 0.531; 0.1; 0.009 ¹²	0.519; 0.127; 0.019 ² 0.840; 0.127; 0.011 ⁵
v_e (Tofts extended model)	0.118; 0.049; 0.004 ⁸ 0.407; 0.095; 0.007 ⁹ 0.377; 0.068; 0.006 ¹²	0.518; 0.138; 0.02 ² 0.795; 0.115; 0.02 ⁵
v_p (Tofts extended model)	0.043; 0.029; 0.003 ⁸ 0.036; 0.024; 0.002 ⁹ 0.175; 0.047; 0.004 ¹²	0.031; 0.035; 0.01 ² 0.097; 0.031; 0.01 ⁵
χ^2 (Tofts model)	273; 113; 10 ⁸ 122; 39; 3 ⁹ 254; 68; 6 ¹²	250; 164; 24 ² 241; 76; 7 ⁵
χ^2 (Tofts extended model)	302; 122; 11 ⁸ 106; 31; 2 ⁹ 180; 38; 4 ¹²	221; 122; 18 ² 160; 48; 4 ⁵

^a The superscript shows the patient number. Data are mean, SD, and 95% confidence value.